sub:assertion {
d:DB04897 v:identifier "DB04897" ;
v:namespace "drugbank" ;
v:uri "http://bio2rdf.org/drugbank:DB04897" ;
v:x-identifiers.org <
http://identifiers.org/drugbank/DB04897> ;
dv:drugbank-id "DB04897" ;
dv:x-ahfs <
http://bio2rdf.org/ahfs:48:36> ;
dv:x-atc <
http://bio2rdf.org/atc:R07AA30> ;
dv:x-cas <
http://bio2rdf.org/cas:825600-90-6> ;
dv:x-wikipedia <
http://bio2rdf.org/wikipedia:Lucinactant> ;
dct:description "Lucinactant is a new synthetic peptide-containing surfactant for intratracheal use. It contains sinapultide, a novel, hydrophobic, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human surfactant protein-B (SB-P). More specifically, it mimics the C-terminal amphipathic helical domain of this protein. It also consists of phospholipids (dipalmitoylphosphatidylcholine, DPPC and palmitoyloleoyl phosphatidylglycerol, POPG) and a fatty acid (palmitic acid). It is completely devoid of animal-derived components. FDA approved on March 6, 2012."@en ;
dct:identifier "drugbank:DB04897" ;
dct:title "Lucinactant"@en ;
a dv:Drug ;
rdfs:label "Lucinactant [drugbank:DB04897]"@en ;
rdfs:seeAlso <
http://www.drugbank.ca/drugs/DB04897> , <
http://www.drugs.com/mtm/lucinactant.html> , <
http://www.rxlist.com/surfaxin-drug.htm> .
}